Effect of Casilan® on 13C-caffeine metabolism in overnight-fasted healthy Nigerian children

ABSTRACT

Objective: To determine the effect of Casilan® on 13C-caffeine metabolism in healthy Nigerian children. Materials and Methods: Twelve healthy Nigerian children (male: six, female: six) aged 3–8 years were studied on three occasions. After an overnight fast, the children were studied after ingesting Casilan® only (Week 1). They were restudied after ingesting 3 mg/kg of labeled caffeine only (Week 2), and further re-studied after ingesting both Casilan® and labeled caffeine (Week 3). Breath samples were collected by blowing via a straw into an exentainer bottle. The cumulative percentage of 13C-caffeine exhaled as 13CO2 was measured over 2 h. Results: The time courses of 13C-enrichments in exhaled CO2 for all the children, after they had ingested labeled caffeine only and after they had ingested both Casilan® and labeled caffeine, were identical. There was a gradual rise and peak of the enrichments at about 60–75 min, followed by a gradual fall (II) or a plateau (III). Contrarily, the time course of 13C-enrichments for all the children was consistently low and stable after they had ingested Casilan® only (I). The mean values of cumulative percent 13C-doses recovered in the CO2 exhaled over a 2-h period, after ingesting labeled caffeine only (8.59 ± 1.10 δ%/mg) and after ingesting both Casilan® and labeled caffeine (8.58 ± 1.33 δ%/mg), were identical, with no statistically significant difference (P = 0.972). This suggests that Casilan® did not affect the CYP1A2 metabolic pathway. Conclusions: Casilan® is a safe, reliable and quantitative food supplement for overnight-fasted children undergoing caffeine breath test.

KEYWORDS

• CYP1A2 metabolizing enzyme
• food supplement
• healthy children
• labeled caffeine

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.4103/0976-500X.107648Copy

RELATED ARTICLES

Matched on section and article type within this issue of J Pharmacol. Pharmacother..

• Article · VOLUME 4, ISSUE 1Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trialShalini Chawla, Nitin Kaushik, Narinder Pal Singh, Raktim Kumar Ghosh, Alpana Saxena · pp. 27–32Research PaperSame type: Article
• Article · VOLUME 4, ISSUE 1Comparison of the efficacy and tolerability of ivabradine and ranolazine in patients of chronic stable angina pectorisAditi Chaturvedi, Yogendra Singh, Harish Chaturvedi, Vijay Thawani, Sakshi Singla, Deepak Parihar · pp. 33–33Research PaperSame type: Article
• Article · VOLUME 4, ISSUE 1Efficacy and safety of Tinospora cordifolia lotion in Sarcoptes scabiei var hominis‑infected pediatric patients: A single blind, randomized controlled trialAgnes L. Castillo, Marina O. Osi, John Donnie A. Ramos, Jean L. De Francia, Marylaine U. Dujunco, Peter F. Quilala · pp. 39–46Research PaperSame type: Article
• Article · VOLUME 4, ISSUE 1Oleanolic acid prevents progression of streptozotocin induced diabetic nephropathy and protects renal microstructures in Sprague Dawley ratsVishal K. Dubey, Chandragouda R. Patil, Sarika M. Kamble, Priti S. Tidke, Kalpesh R. Patil, Pragnesh J. Maniya, Ramchandra B. Jadhav, Sudha P. Patil · pp. 47–52Research PaperSame type: Article